Managing IP is part of Legal Benchmarking Limited, 4 Bouverie Street, London, EC4Y 8AX

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Search results for

There are 20,677 results that match your search.20,677 results
  • Genentech's settlement with the University of California has just cost the San Francisco company a cool $200 million
  • Last year we witnessed celebrations of significant anniversaries connected with patent offices and IP rights in Germany and Austria. Meanwhile, the Czech Patent Office quietly marked the 80th anniversary of its foundation in 1919.
  • Trade marks which, either intrinsically, or because they are popular on the market, have a clear distinctiveness, enjoy a broader degree of protection than trade marks which are less distinctive. This criterion emerged from the ruling handed down by the ECJ on November 11 1997 in the Puma v Sabel case. The question of when a trade mark is well-known has remained unanswered for some time. However, although this question has a bearing on the application of Article 5, Paragraph 2 of the Trade Mark Directive and of Section 13A, Subsection 1 under c of the Uniform Benelux Trade Marks Act which stipulates that the owner of a well-known trade mark can oppose the use thereof or of a similar sign for dissimilar goods or services if such use can result in an unfair advantage being derived from the trade mark or the distinctiveness or reputation of the trade mark being impaired.
  • Filing @ USPTO
  • USPTO demands review of Y2K
  • Chipie wins global victory
  • UK & Netherlands: European law firm Eversheds and leading Netherlands practice Boekel De Nerée merged on January 1 2000. The new firm combines Boekel De Nerée's 250 staff and Eversheds' 3,300 staff.
  • Rouse in new venture
  • US: A federal judge in San Francisco ruled December 7 that a patent for DNA analysis owned by Swiss biotechnology company Hoffman-La Roche was obtained by deliberately misleading the USPTO and is invalid. US District Judge Vaughn Walker upheld a challenge by Promega which argued that scientists got the patent in 1990 through false claims. Those scientists worked for Cetus, which sold rights to the patent to Hoffman La Roche in 1991. The patented substance is called Taq DNA Polymerase. Cetus inventors had convinced the patent office that they had a substance better than those developed in the 1980s. Hoffman-La Roche is appealing, and contends that the ruling invalidates the patent for only one form of Taq, and not for the more common and lucrative recombinant Taq.
  • Brazilian reform provokes alarm